Shares of argenx SE (NASDAQ:ARGX – Get Rating) have earned an average recommendation of “Buy” from the eighteen brokerages that are covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a hold recommendation, fourteen have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price target among analysts that have covered the stock in the last year is $390.67.
ARGX has been the subject of a number of research reports. Stifel Nicolaus upped their target price on shares of argenx from $460.00 to $471.00 in a report on Thursday, July 28th. HC Wainwright upped their target price on shares of argenx from $400.00 to $425.00 and gave the stock a “buy” rating in a report on Friday, July 29th. SVB Leerink boosted their price target on shares of argenx from $404.00 to $428.00 and gave the company an “outperform” rating in a research report on Friday, July 29th. JPMorgan Chase & Co. boosted their price target on shares of argenx from €390.00 ($402.06) to €430.00 ($443.30) and gave the company an “overweight” rating in a research report on Thursday, July 14th. Finally, Robert W. Baird reissued a “downgrade” rating on shares of argenx in a research report on Friday, July 29th.
argenx Stock Down 0.3 %
argenx stock opened at $367.85 on Monday. argenx has a 52-week low of $249.50 and a 52-week high of $387.89. The company has a fifty day simple moving average of $353.35 and a 200-day simple moving average of $316.84.
Institutional Trading of argenx
Institutional investors have recently modified their holdings of the company. Connor Clark & Lunn Investment Management Ltd. raised its position in argenx by 1,055.8% during the second quarter. Connor Clark & Lunn Investment Management Ltd. now owns 10,009 shares of the company’s stock valued at $3,792,000 after buying an additional 9,143 shares during the period. Glassman Wealth Services increased its position in argenx by 69.4% in the 2nd quarter. Glassman Wealth Services now owns 83 shares of the company’s stock worth $31,000 after purchasing an additional 34 shares during the last quarter. Steward Partners Investment Advisory LLC increased its position in argenx by 71.3% in the 2nd quarter. Steward Partners Investment Advisory LLC now owns 298 shares of the company’s stock worth $113,000 after purchasing an additional 124 shares during the last quarter. Envestnet Asset Management Inc. boosted its stake in shares of argenx by 3.8% during the 2nd quarter. Envestnet Asset Management Inc. now owns 13,511 shares of the company’s stock worth $5,119,000 after acquiring an additional 499 shares in the last quarter. Finally, Assetmark Inc. boosted its stake in shares of argenx by 40.4% during the 2nd quarter. Assetmark Inc. now owns 2,094 shares of the company’s stock worth $793,000 after acquiring an additional 603 shares in the last quarter. Institutional investors and hedge funds own 58.76% of the company’s stock.
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, and chronic inflammatory demyelinating polyneuropathy in Phase III clinical trials; bullous pemphigoid and idiopathic inflammatory myopathy in Phase II/III clinical trials; and ENHANZE SC in Pre-clinical study.
- Get a free copy of the StockNews.com research report on argenx (ARGX)
- MarketBeat: Week in Review 8/1 – 8/5
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Cronos Group Inc’s Revenues Are Up, Is It Time to Buy?
- Beyond Meat Is Not Beyond Hope, And It’s Cheap
- Why Apple Could Be At All-Time Highs By Year End
Receive News & Ratings for argenx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for argenx and related companies with MarketBeat.com's FREE daily email newsletter.